Literature DB >> 30662608

Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition.

Xin-Yu Zhang1,2, Ping-Ting Gao1,2, Xuan Yang1,2, Jia-Bin Cai1,2, Guang-Yu Ding1,2, Xiao-Dong Zhu1,2, Yuan Ji3, Guo-Ming Shi1,2, Ying-Hao Shen1,2, Jian Zhou1,2, Jia Fan1,2, Hui-Chuan Sun1,2, Liu-Xiao Yang4, Cheng Huang1,2.   

Abstract

Recent studies have found that selenium-binding protein 1 (SBP1) is downregulated in various malignant tumors. Nevertheless, the role of SBP1 in intrahepatic cholangiocarcinoma (ICC) is largely unknown. In the present study, we aimed to explore the clinical significance and biological function of SBP1 in ICC. Western blotting and immunohistochemistry were performed to evaluate SBP1 expression in ICC tissues, and correlations between SBP1 and clinicopathological parameters were further assessed. The prognostic significance of SBP1 in ICC patients was evaluated via Kaplan-Meier and Cox regression analyses. Moreover, we used RBE, a human ICC cell line, to study the effects of SBP1 knockdown on ICC cell proliferation, migration and invasion. Finally, the expression levels of epithelial-mesenchymal transition-related markers, including snail, vimentin, and E-cadherin, were investigated via Western blotting and immunohistochemistry. The results showed that SBP1 expression was significantly downregulated in ICC tumor tissues, especially in tumor tissues from ICC patients with recurrence or tumor vascular invasion, compared with that in peritumoral tissues (all P < 0.05). In addition, the reduction in SBP1 expression was related to microvascular invasion, lymphatic metastasis, and tumor-node-metastasis (TNM) stage (all P < 0.05). Furthermore, the SBP1 expression level was an independent prognostic factor in ICC (P < 0.05). Knockdown of SBP1 resulted in decreased in vitro proliferation, migration and invasion ability. Low SBP1 expression also resulted in the upregulation of mesenchymal markers such as vimentin and snail. In conclusion, SBP1 may be a prognostic indicator for patients with ICC as well as a potential target for ICC treatment.

Entities:  

Keywords:  Selenium-binding protein 1; epithelial-mesenchymal transition; intrahepatic cholangiocarcinoma; prognosis

Year:  2018        PMID: 30662608      PMCID: PMC6291736     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  5 in total

1.  MicroRNA‑137 suppresses the proliferation, migration and invasion of cholangiocarcinoma cells by targeting WNT2B.

Authors:  Tengxiang Chen; Shan Lei; Zhirui Zeng; Shutao Pan; Jinjuan Zhang; Yan Xue; Yuanmei Sun; Jinzhi Lan; Su Xu; Dahua Mao; Bing Guo
Journal:  Int J Mol Med       Date:  2020-01-23       Impact factor: 4.101

2.  Selenium-binding protein 1 transcriptionally activates p21 expression via p53-independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer.

Authors:  Yulei Wang; Wenzhen Zhu; Xiaoqing Chen; Guangnan Wei; Guosong Jiang; Guochun Zhang
Journal:  J Transl Med       Date:  2020-01-09       Impact factor: 5.531

3.  Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma.

Authors:  Lei Zhang; Zhe Zhang; Zhenglun Yu
Journal:  J Transl Med       Date:  2019-12-17       Impact factor: 5.531

4.  SELENBP1 inhibits progression of colorectal cancer by suppressing epithelial-mesenchymal transition.

Authors:  Xiaotian Zhang; Runqi Hong; Lanxin Bei; Zhiqing Hu; Ximin Yang; Tao Song; Liang Chen; He Meng; Gengming Niu; Chongwei Ke
Journal:  Open Med (Wars)       Date:  2022-09-01

5.  Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma.

Authors:  Yang Cheng; Kezuo Hou; Yizhe Wang; Yang Chen; Xueying Zheng; Jianfei Qi; Bowen Yang; Shiying Tang; Xu Han; Dongyao Shi; Ximing Wang; Yunpeng Liu; Xuejun Hu; Xiaofang Che
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.